Literature DB >> 18932235

Treatment and prognosis of hepatocellular carcinoma: a population based study in France.

Frédéric Borie1, Anne-Marie Bouvier, Astrid Herrero, Jean Faivre, Guy Launoy, Patricia Delafosse, Michel Velten, Antoine Buemi, Jun Peng, Pascale Grosclaude, Brigitte Trétarre.   

Abstract

OBJECTIVE: Few data are available from population-based statistics on hepatocellular carcinoma (HCC). The aim of this study was to report on their management and their prognosis in a French population.
METHODS: Between 1997 and 1998, 1,007 cases of HCC were registered in nine French departments: clinical presentation of patients with and without cirrhosis were compared as well as treatment. Prognosis was determined using crude and relative survival rates. A multivariate relative survival analysis was performed. HCC was associated with cirrhosis in 795 patients (79%) and to the absence of cirrhosis in 156 (15%).
RESULTS: Whereas the presence of symptoms was the principal mode of discovery (63% of cirrhotic cases and 70% of non-cirrhotic cases), the follow-up of hepatic affections revealed the cancer in respectively 26% and 3% (P = 0.001). The diagnosis was histologically verified in 50% of cirrhotic patients and 80% of non-cirrhotic patients (P = 0.01). The size of tumours was significantly greater in non-cirrhotic than in cirrhotic cases (P = 0.004). Treatment for cure were implemented in respectively 15% and 30% (P = 0.001), resulting in 5-year survival rates of respectively 34% and 28%. Only 24 HCC cases received a liver transplant, with a 5-year survival rate of 60%. Surgical resection for cure was carried out in respectively 10% and 31% of HCC and HCNC cases (P = 0.001), with a 5-year survival rate of respectively 39% and 29%. The overall 5-year survival rates of HCC and HCNC were respectively 6% and 9%.
CONCLUSION: HCC with and without cirrhosis has a poor prognosis with the majority of patients receiving palliative treatments, the efficiency of which is very limited. Considerable efforts are needed to develop primary and secondary prevention. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18932235     DOI: 10.1002/jso.21159

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  23 in total

1.  Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations.

Authors:  Peter Chianchiano; Maryam Kherad Pezhouh; Amy Kim; Claudio Luchini; Andrew Cameron; Matthew J Weiss; Jin He; Lysandra Voltaggio; Kiyoko Oshima; Robert A Anders; Laura D Wood
Journal:  Hum Pathol       Date:  2017-11-24       Impact factor: 3.466

Review 2.  Radiofrequency Ablation, Where It Stands in Interventional Radiology Today.

Authors:  Vipulkumar Patel; Charles A Ritchie; Carlos Padula; J Mark McKinney
Journal:  Semin Intervent Radiol       Date:  2019-12-02       Impact factor: 1.513

3.  What we learned from difficult hepatectomies in patients with advanced hepatic malignancy.

Authors:  Bo Hyun Jung; Jae Hoon Lee; Sang Yeup Lee; Dae Keun Song; Ji Woong Hwang; Dae Wook Hwang; Young-Joo Lee; Kwang-Min Park
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2011-12-15

Review 4.  Surgical treatment for liver cancer.

Authors:  Nicole C Tsim; Adam E Frampton; Nagy A Habib; Long R Jiao
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

5.  Heat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer.

Authors:  Sai Zhang; Yangmin Hu; Yuwen Huang; Huimin Xu; Gongxiong Wu; Haibin Dai
Journal:  Oncol Lett       Date:  2015-03-26       Impact factor: 2.967

6.  Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease.

Authors:  Kerstin Schütte; Jan Bornschein; Stefan Kahl; Ricarda Seidensticker; Jörg Arend; Jens Ricke; Peter Malfertheiner
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

7.  New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis.

Authors:  Kevin David Shield; Claire Marant Micallef; Catherine de Martel; Isabelle Heard; Francis Megraud; Martyn Plummer; Jérôme Vignat; Freddie Bray; Isabelle Soerjomataram
Journal:  Eur J Epidemiol       Date:  2017-12-06       Impact factor: 8.082

8.  Percutaneous radiofrequency ablation for early hepatocellular carcinoma: risk factors for survival.

Authors:  Luciana Kikuchi; Marcos Menezes; Aline L Chagas; Claudia M Tani; Regiane Ssm Alencar; Marcio A Diniz; Venâncio Af Alves; Luiz Augusto Carneiro D'Albuquerque; Flair José Carrilho
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

9.  Recurrence of hepatocellular carcinoma in noncirrhotic liver after hepatectomy.

Authors:  Laurence Chiche; B Menahem; C Bazille; V Bouvier; L Plard; V Saguet; A Alves; E Salame
Journal:  World J Surg       Date:  2013-10       Impact factor: 3.352

10.  Comparison of 10-Year Survival Outcomes for Early Single Hepatocellular Carcinoma following Different Treatments.

Authors:  Fanyu Meng; Haoyun Zhang; Haiwen Peng; Shichun Lu
Journal:  Biomed Res Int       Date:  2021-03-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.